Improving the Estimation of Subgroup Effects for Clinical Trial Participants with Multimorbidity by Incorporating Drug Class-Level Information in Bayesian Hierarchical Models: A Simulation Study

Laurie J. Hannigan, David M. Phillippo, Peter Hanlon, Laura Moss, Elaine W. Butterly, Neil Hawkins, Sofia Dias, Nicky J. Welton and David A. McAllister
Additional contact information
Laurie J. Hannigan: Nic Waals Institute, Lovisenberg Diaconal Hospital, Oslo, Norway
David M. Phillippo: Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
Peter Hanlon: Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
Laura Moss: NHS Greater Glasgow & Clyde, UK
Elaine W. Butterly: Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
Neil Hawkins: Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
Sofia Dias: Centre for Reviews and Dissemination, University of York, York, North Yorkshire, UK
Nicky J. Welton: Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
David A. McAllister: Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK

Medical Decision Making, 2022, vol. 42, issue 2, 228-240

Abstract: Background There is limited guidance for using common drug therapies in the context of multimorbidity. In part, this is because their effectiveness for patients with specific comorbidities cannot easily be established using subgroup analyses in clinical trials. Here, we use simulations to explore the feasibility and implications of concurrently estimating effects of related drug treatments in patients with multimorbidity by partially pooling subgroup efficacy estimates across trials. Methods We performed simulations based on the characteristics of 161 real clinical trials of noninsulin glucose-lowering drugs for diabetes, estimating subgroup effects for patients with a hypothetical comorbidity across related trials in different scenarios using Bayesian hierarchical generalized linear models. We structured models according to an established ontology—the World Health Organization Anatomic Chemical Therapeutic Classifications—allowing us to nest all trials within drugs and all drugs within anatomic chemical therapeutic classes, with effects partially pooled at each level of the hierarchy. In a range of scenarios, we compared the performance of this model to random effects meta-analyses of all drugs individually. Results Hierarchical, ontology-based Bayesian models were unbiased and accurately recovered simulated comorbidity-drug interactions. Compared with single-drug meta-analyses, they offered a relative increase in precision of up to 250% in some scenarios because of information sharing across the hierarchy. Because of the relative precision of the approaches, a large proportion of small subgroup effects was detectable only using the hierarchical model. Conclusions By assuming that similar drugs may have similar subgroup effects, Bayesian hierarchical models based on structures defined by existing ontologies can be used to improve the precision of treatment efficacy estimates in patients with multimorbidity, with potential implications for clinical decision making.

Keywords: hierarchical modeling; individual-patient data meta-analysis; medical ontologies; multimorbidity; subgroup analysis (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.sagepub.com/doi/10.1177/0272989X211029556 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sae:medema:v:42:y:2022:i:2:p:228-240

DOI: 10.1177/0272989X211029556

Access Statistics for this article

More articles in Medical Decision Making
Bibliographic data for series maintained by SAGE Publications ().